Screener
Syndax Pharmaceuticals SNDX Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue: | ||
| Product revenue, net | $48,923 | $20,042 |
| Collaboration revenue, net | 15,941 | — |
| Total revenues | 64,864 | 20,042 |
| Operating expenses: | ||
| Cost of product sales | $2,633 | $885 |
| Research and development | 58,845 | 61,636 |
| Selling, general and administrative | 37,588 | 41,031 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's total revenue?
- Syndax Pharmaceuticals (SNDX) reported total revenue of $64.86M in Q1 2026.
- How has Syndax Pharmaceuticals's total revenue changed year-over-year?
- Syndax Pharmaceuticals's total revenue increased by 223.6% year-over-year, from $20.04M to $64.86M.
- What is the long-term trend for Syndax Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's total revenue has grown at a 5.4% compound annual growth rate (CAGR), from $139.71M to $172.6M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Syndax Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude